29 April 2019 to 4 May 2019
Erice
Europe/Zurich timezone

Comparison between microPET-based and biodistribution-based dosimetry of a 152Tb-labelled antibody in tumour-bearing mice

30 Apr 2019, 14:30
20m
Ettore Majorana Foundation (Erice)

Ettore Majorana Foundation

Erice

MEDICIS-Promed ESRs Preclinical research and development of new radiopharmaceuticals Ovarian cancer (PART I)

Speaker

Dr Francesco Cicone

Description

Aim. To assess the feasibility of mouse-specific, microPET- based dosimetry of an antibody labelled with 152Tb. Image-based absorbed dose estimates were compared with dosimetry results obtained from the extrapolation to 152Tb of a classical biodistribution experiment using the same antibody fragment labelled with 111In.
Methods. The scFv78-Fc fusion protein targeting TEM-1 was conjugated with the chelator CHX-DTPA, and then labelled with either 152Tb or 111In. Micro-PET images of four female mice bearing sarcoma were acquired 4, 24 and 48 h after the i.v injection of 152Tb-CHX-DTPA-scFv78-Fc. After count/activity camera calibration, time-integrated activity coefficients (TIACs) were obtained for the following compartments: heart content, lungs, liver, kidneys, intestines, tumor and whole body. For comparison, radiation dose estimates of 152Tb-CHX-DTPA-ScFv78-Fc were extrapolated from mice dissected 4, 24, 48 and 96 h after the injection of 111In-CHX-DTPA-scFv78-Fc (3–5 mice per group). Imaging-derived and biodistribution-derived organ TIACs were used as input in the 25 g mouse model of OLINDA2. Tumor absorbed doses were obtained using the OLINDA2 sphere model. Finally, the relative percent difference (RD%) between absorbed doses obtained from imaging and biodistribution were calculated.
Results: RD% between microPET-based dosimetry and biodistribution-based dose extrapolations were +12, –14 and +17 for the liver, the kidneys and the tumors, respectively. Compared to biodistribution, the imaging method significantly overestimates the absorbed doses to the heart and the lungs.
Conclusions: MicroPET-based dosimetry of 152Tb is feasible, and the comparison with organ harvesting resulted in acceptable dose discrepancies for body districts that can be segmented on CT.

Primary authors

Presentation materials

There are no materials yet.